Lung cancer accounts for one of the highest numbers of cancer related deaths, and - among its disease subtypes - HER2 mutations can play a key role in tumour initiation and growth. Unfortunately no targeted therapy is yet available to treat the most common HER2 mutations.

Dr Birgit Wilding, Dr Ralph Neumueller, Dr Flavio Solca, and colleagues at Boehringer Ingelheim have been researching these HER2 mutations,  and have developed drugs that inhibit the abnormal HER2 signalling driving cancer growth. One of the new inhibitors is now undergoing testing in a Phase 1 clinical trial to safely assess the potential of the drug as effective against tumours, and also reducing side-effects.

Read the original research : https://doi.org/10.1038/s43018-022-00412-y